source
- Parker Institute chief urges renewed focus on cancer immunotherapy after mixed results from Revolution Medicines' drugIra Mellman, who leads research at the Parker Institute for Cancer Immunotherapy, said on Sept. 16, 2026 that he felt disappointment and frustration as the industry celebrated Revolution Medicines'…
- Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launchPfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.